Cargando…

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Eshraghi, Abbas, Esfandbod, Mohsen, SafaeiNodehi, Seyed Reza, Shahi, Farhad, Eshraghi, Azhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iran University of Medical Sciences 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320980/ https://www.ncbi.nlm.nih.gov/pubmed/32617278 http://dx.doi.org/10.34171/mjiri.34.39

Ejemplares similares

KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
por: Awidi, Muhammad, et al.
Publicado: (2019)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer
por: OUNISSI, Donia, et al.
Publicado: (2021)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver-only and lung-only metastases
por: Chuang, Shih-Chang, et al.
Publicado: (2020)

A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer
por: Levin-Sparenberg, Elizabeth, et al.
Publicado: (2020)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
por: Nagakubo, Yuki, et al.
Publicado: (2019)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2019)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015
por: Jouini, Raja, et al.
Publicado: (2019)

Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report
por: El agy, Fatima, et al.
Publicado: (2021)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
por: Baltruškevičienė, Edita, et al.
Publicado: (2016)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
por: Momenzadeh, Hooria, et al.
Publicado: (2018)

KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation
por: Lastraioli, Elena, et al.
Publicado: (2021)

Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series
por: Mahdi, Youssef, et al.
Publicado: (2023)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study
por: Sanchez-Ibarra, Hector Eduardo, et al.
Publicado: (2020)

Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases
por: Formica, Vincenzo, et al.
Publicado: (2020)

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11
por: Taniguchi, Hiroya, et al.
Publicado: (2015)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
por: Zeng, Juanzi, et al.
Publicado: (2023)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

Dysbiosis of fecal microbiota and high frequency of Citrobacter, Klebsiella spp., and Actinomycetes in patients with irritable bowel syndrome and gastroenteritis
por: Ganji, Leila, et al.
Publicado: (2016)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

Pretreatment (18)F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer
por: He, Peng, et al.
Publicado: (2021)

NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
por: Yang, Tianyou, et al.
Publicado: (2019)

The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia
por: Rinonce, Hanggoro Tri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n0i74i3hreask6urpf5q57h8ii